Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib in the treatment of advanced squamous cell NSCLC.

Neoplasma - 1 Jan 2013

Fiala O, Pesek M, Finek J, Krejci J, Havel L, Hrnciarik M, Salajka F, Bortlicek Z, Benesova L, Minarik M

Abstract excerpt

Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor. Clinical trials have shown its efficacy in advanced non-small cell lung cancer (NSCLC). We conducted a large retrospective study based on clinical experience aiming to prove erlotinib's efficacy and safety in patients wit...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Carcinoma, Squamous Cell
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Survival Rate

Source

Identifiers

PMID: 23906302
DOI: 10.4149/neo_2013_086

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23906302-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib in the treatment of advanced squamous cell NSCLC.PMID 23906302Read ↗

Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.Semantic proximity Read ↗

Erlotinib in the first-line treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.Semantic proximity Read ↗

Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.Semantic proximity Read ↗

Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.Semantic proximity Read ↗

Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).Semantic proximity Read ↗

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.Semantic proximity Read ↗

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.Semantic proximity Read ↗

Experience with erlotinib in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker.Semantic proximity Read ↗

Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.Semantic proximity Read ↗

[Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.